Biomaterials Market Size, Share and Growth Outlook, 2026

Biomaterials Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Biomaterials Market size is forecast to increase from $53.25 Billion in 2026 to $96.39 Billion in 2034 at a CAGR of 7.7% between 2026 and 2034.

The Biomaterials market report provides detailed analysis and outlook of Biomaterials segments including By Type (Metallic Biomaterials, Polymeric Biomaterials, Ceramic Biomaterials, Natural Biomaterials), By Application (Orthopedics, Cardiovascular, Dental, Ophthalmology, Wound Healing, Tissue Engineering, Neurological, Plastic Surgery) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Biomaterials Industry Overview

Biopolymer Innovation Driving Next-Generation Biomaterial Development

The biomaterials industry is undergoing significant transformation as manufacturers accelerate the development of sustainable, high-performance materials for healthcare, packaging, industrial, and consumer applications. A major advancement in this area comes from Teknor Apex Co., which secured exclusive worldwide rights to manufacture and sublicense a proprietary biomaterial technology developed by Cerestech Inc. The technology enables vegetable-derived Thermoplastic Starch (TPS) to be blended with conventional bioplastics such as polylactic acid (PLA) and polyhydroxyalkanoate (PHA), as well as traditional petrochemical-based resins. The resulting biomaterial masterbatches retain key physical properties, including mechanical strength and moisture resistance, overcoming common performance limitations associated with biodegradable materials. To support commercialization and further product development, Teknor Apex established a dedicated compounding pilot plant at its Rhode Island headquarters, highlighting growing investment in scalable sustainable biomaterial production.

Manufacturing Expansion Strengthening Biodegradable Material Supply Chains

Strategic acquisitions are playing an increasingly important role in expanding global biomaterial manufacturing capabilities. Following the restructuring of several biopolymer enterprises, Teknor Apex completed the acquisition of Danimer Scientific’s operational assets. This transaction added more than 200,000 square feet of manufacturing capacity through two specialized bio-manufacturing facilities. The acquisition significantly enhances Teknor Apex’s ability to produce biodegradable polyhydroxyalkanoate (PHA) materials at commercial scale for major retail, packaging, and consumer goods applications. As demand for environmentally responsible materials continues to rise, manufacturers are investing in production infrastructure capable of supporting large-scale adoption of biodegradable polymers across diverse end-use sectors. These developments reflect the industry's broader transition toward renewable feedstocks, circular economy initiatives, and sustainable material solutions.

Medical-Grade Polymers Expanding Healthcare Applications

The healthcare segment remains a major growth area within the biomaterials industry as medical device manufacturers increasingly seek advanced implantable and biocompatible materials. Solvay expanded its healthcare materials portfolio through the introduction of its Solviva Biomaterials platform into the Brazilian market. The portfolio includes high-purity implant-grade polymers such as specialty polyether ether ketone (PEEK) and advanced sulfone-based materials engineered for medical and surgical applications. These biomaterials provide localized sourcing opportunities for South American medical device manufacturers while supporting stringent biocompatibility and performance requirements. The growing adoption of implant-grade polymers reflects increasing demand for durable, lightweight, and biologically compatible materials used in orthopedic implants, surgical instruments, dental devices, and other advanced healthcare technologies. As regional healthcare manufacturing capabilities continue to expand, specialized biomaterials are becoming increasingly important for supporting innovation in medical device design and patient care.

Biomaterials Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Biomaterials market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- BASF SE, Evonik Industries AG, DSM-Firmenich (Royal DSM), Covestro AG, Celanese Corporation, Corbion N.V., Zimmer Biomet, Victrex plc, Carpenter Technology Corporation, Nobel Biocare (Danaher Corporation). The Biomaterials market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Biomaterials industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Biomaterials Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Biomaterials companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Biomaterials markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Biomaterials Market Competitive Benchmarking and Company Analysis

Leading companies in Biomaterials industry include- BASF SE, Evonik Industries AG, DSM-Firmenich (Royal DSM), Covestro AG, Celanese Corporation, Corbion N.V., Zimmer Biomet, Victrex plc, Carpenter Technology Corporation, Nobel Biocare (Danaher Corporation). The Biomaterials market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Biomaterials Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Biomaterials market remains one of the strongest-performing segments in the country.
The US Biomaterials Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Biomaterials market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Biomaterials industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Biomaterials markets

Canada's strong Biomaterials sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Biomaterials market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Biomaterials Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Biomaterials market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Biomaterials population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Biomaterials industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Biomaterials market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Biomaterials sales through 2034

France Biomaterials companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Biomaterials Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Biomaterials distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Biomaterials Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Biomaterials market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Biomaterials industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Biomaterials industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Biomaterials Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Biomaterials market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Biomaterials market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Biomaterials Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Biomaterials Market Segmentation

By Type
Metallic Biomaterials
Polymeric Biomaterials
Ceramic Biomaterials
Natural Biomaterials
By Application
Orthopedics
Cardiovascular
Dental
Ophthalmology
Wound Healing
Tissue Engineering
Neurological
Plastic Surgery

Top Companies in Biomaterials Industry

BASF SE
Evonik Industries AG
DSM-Firmenich (Royal DSM)
Covestro AG
Celanese Corporation
Corbion N.V.
Zimmer Biomet
Victrex plc
Carpenter Technology Corporation
Nobel Biocare (Danaher Corporation)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa